Log in

OTCMKTS:ESALYEisai Stock Price, Forecast & News

$70.62
-0.39 (-0.55 %)
(As of 05/25/2020 04:00 PM ET)
Add
Compare
Today's Range
$70.10
Now: $70.62
$70.81
50-Day Range
$65.19
MA: $69.49
$74.57
52-Week Range
$48.52
Now: $70.62
$90.82
Volume7,959 shs
Average Volume4,263 shs
Market Capitalization$20.94 billion
P/E Ratio18.06
Dividend Yield1.78%
Beta0.44
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. It develops Fycompa, an antiepileptic drug in the neurology area that is approved as an adjunctive therapy for partial-onset seizures in Japan, the United States, Europe, and Asia. The company is also approved for use as monotherapy for the treatment of partial onset seizures in the United States; and as an adjunctive therapy for primary generalized tonic-clonic seizures in Japan, the United States, Europe, and Asia. It also offers Aricept for the treatment of Alzheimer's disease/dementia with Lewy bodies worldwide; and BELVIQ, an antiobesity agent in the United States. In addition, it develops Halaven, an anticancer agent in the oncology area for use in the treatment of breast cancer in approximately 65 countries and also for use in the treatment of malignant soft tissue sarcoma in 50 countries; and Lenvima, an anticancer agent for use in the treatment of thyroid cancer in Japan, the United States, Europe, and Asia. Further, the company has been approved as combination therapy with everolimus for use in the treatment of renal cell carcinoma in the United States and Europe. It has strategic collaboration with Merck & Co., Inc. for Lenvima in the oncology and dementia fields; and with Ono Pharmaceutical Co., Ltd. for Lenvima and Opdivo combination therapy for the treatment of hepatocellular carcinoma, as well as Collaboration Agreement with Ono Pharmaceutical Co., Ltd. to develop a therapy for treatment of hepatocellular carcinoma. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.
Read More
Eisai logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 3.3Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.44 out of 5 stars


Industry, Sector and Symbol

Industry Private households
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ESALY
CUSIPN/A
Phone813-3817-3700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.40 billion
Cash Flow$2.83 per share
Book Value$20.48 per share

Profitability

Net Income$1.12 billion

Miscellaneous

Employees10,456
Market Cap$20.94 billion
Next Earnings Date7/29/2020 (Estimated)
OptionableNot Optionable

Receive ESALY News and Ratings via Email

Sign-up to receive the latest news and ratings for ESALY and its competitors with MarketBeat's FREE daily newsletter.

Eisai (OTCMKTS:ESALY) Frequently Asked Questions

How has Eisai's stock been impacted by COVID-19 (Coronavirus)?

Eisai's stock was trading at $72.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ESALY stock has decreased by 3.1% and is now trading at $70.6215. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Eisai?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eisai in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Eisai.

When is Eisai's next earnings date?

Eisai is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Eisai.

Has Eisai been receiving favorable news coverage?

News coverage about ESALY stock has been trending positive recently, according to InfoTrie. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Eisai earned a news sentiment score of 2.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an impact on the company's share price in the near term. View the latest news aboutEisai.

Who are some of Eisai's key competitors?

Who are Eisai's key executives?

Eisai's management team includes the following people:
  • Mr. Haruo Naito, CEO, Representative Corp. Officer & Director (Age 72)
  • Mr. Gary Hendler, Sr. VP & Pres of EMEA Region (Age 53)
  • Dr. Lynn D. Kramer, VP and Chief Clinical Officer & Chief Medical Officer - Neurology Bus. Group (Age 69)
  • Mr. Alexander Scott, VP, Chief Strategy Officer & Head of Strategy Dept. - Neurology Bus. Group
  • Ms. Shaji Procida, VP and Pres & COO of Eisai Inc. (Age 48)

What is Eisai's stock symbol?

Eisai trades on the OTCMKTS under the ticker symbol "ESALY."

How do I buy shares of Eisai?

Shares of ESALY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eisai's stock price today?

One share of ESALY stock can currently be purchased for approximately $70.62.

How big of a company is Eisai?

Eisai has a market capitalization of $20.94 billion and generates $6.40 billion in revenue each year. The company earns $1.12 billion in net income (profit) each year or $3.91 on an earnings per share basis. Eisai employs 10,456 workers across the globe.

What is Eisai's official website?

The official website for Eisai is www.eisai.co.jp.

How can I contact Eisai?

Eisai's mailing address is 4-6-10 Koishikawa Bunkyo-ku, Tokyo M0, 112-8088. The company can be reached via phone at 813-3817-3700.

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.